Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovidâs most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). Source
No articles found.
MedChain's mission is to use blockchain technology to establish a better, more sec...
MedChain's mission is to use blockchain technol...
For over 20 years Streamline Health has provided solutions that address the fundam...
For over 20 years Streamline Health has provide...
REGENXBIO is a leading biotechnology company focused on the development, commercia...
REGENXBIO is a leading biotechnology company fo...
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Join the National Investor Network and get the latest information with your interests in mind.